AR051904A1 - Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r) - Google Patents

Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)

Info

Publication number
AR051904A1
AR051904A1 ARP060100168A ARP060100168A AR051904A1 AR 051904 A1 AR051904 A1 AR 051904A1 AR P060100168 A ARP060100168 A AR P060100168A AR P060100168 A ARP060100168 A AR P060100168A AR 051904 A1 AR051904 A1 AR 051904A1
Authority
AR
Argentina
Prior art keywords
neuropeptide
peptides
receiver
agonist activity
obesity
Prior art date
Application number
ARP060100168A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR051904A1 publication Critical patent/AR051904A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a agonistas del receptor del neuropéptido-2 de la formula: Y-R1-R2-X-R3-R4-R5-R6-R7-R8-R9-R10-R11-R12-R13-R14-NH2, así como sales farmacéuticamente aceptables, derivados y fragmentos de los mismos, donde los sustituyentes son como aquellos discutidos en la especificacion. Estos compuestos, y las composiciones farmacéuticas que las contienen, son utiles para el tratamiento de enfermedades como, por ejemplo, obesidad.
ARP060100168A 2005-01-18 2006-01-16 Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r) AR051904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64484005P 2005-01-18 2005-01-18

Publications (1)

Publication Number Publication Date
AR051904A1 true AR051904A1 (es) 2007-02-14

Family

ID=36118121

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100168A AR051904A1 (es) 2005-01-18 2006-01-16 Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)

Country Status (22)

Country Link
US (1) US7410949B2 (es)
EP (1) EP1844070B1 (es)
JP (1) JP4633804B2 (es)
KR (1) KR100905380B1 (es)
CN (1) CN101107266A (es)
AR (1) AR051904A1 (es)
AT (1) ATE500268T1 (es)
AU (1) AU2006207659B2 (es)
BR (1) BRPI0606675A2 (es)
CA (1) CA2594423A1 (es)
DE (1) DE602006020407D1 (es)
DK (1) DK1844070T3 (es)
ES (1) ES2359850T3 (es)
IL (1) IL184428A0 (es)
MX (1) MX2007008614A (es)
NO (1) NO20073664L (es)
PL (1) PL1844070T3 (es)
PT (1) PT1844070E (es)
RU (1) RU2383553C2 (es)
TW (1) TWI309653B (es)
WO (1) WO2006077035A1 (es)
ZA (1) ZA200705674B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568772A (en) * 2005-12-07 2010-05-28 Hoffmann La Roche Truncated analogs of the peptide pYY3-36 that are neuropeptide-2 receptor-agonists
US8299023B2 (en) * 2008-09-17 2012-10-30 Hoffmann-La Roche Inc. Neuropeptide-2 receptor (Y-2R) agonists
EP2352511A2 (en) * 2008-11-05 2011-08-10 F. Hoffmann-La Roche AG Neuropeptide-2-receptor (y-2r) agonists and uses thereof
WO2011002066A1 (ja) * 2009-07-02 2011-01-06 武田薬品工業株式会社 ペプチド及びその用途
EP2477643A1 (en) * 2009-09-18 2012-07-25 Novo Nordisk A/S Long-acting y2 receptor agonists
EP2488195A2 (en) * 2009-10-13 2012-08-22 F. Hoffmann-La Roche AG Neuropeptide-2 receptor (y-2r) agonists
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
HUE062740T2 (hu) 2012-03-22 2023-12-28 Novo Nordisk As GLP-1 peptidek készítményei és elõállításuk
CA2872213A1 (en) 2012-06-13 2013-12-19 F. Hoffmann-La Roche Ag New diazaspirocycloalkane and azaspirocycloalkane
UA116547C2 (uk) 2012-09-25 2018-04-10 Ф. Хоффманн-Ля Рош Аг Біциклічні похідні
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
SI3068421T1 (sl) 2013-11-15 2019-08-30 Novo Nordisk A/S Selektivne spojine PYY in njihova uporaba
EP3068795B1 (en) 2013-11-15 2019-03-06 Novo Nordisk A/S Hpyy(1-36) having a beta-homoarginine substitution at position 35
CN105764905B (zh) 2013-11-26 2019-06-07 豪夫迈·罗氏有限公司 新的八氢-环丁二烯并[1，2-c；3，4-c’]二吡咯-2基
CA2935612A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
HUE046820T2 (hu) 2014-03-26 2020-03-30 Hoffmann La Roche Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
BR112017025108A2 (pt) 2015-06-12 2018-07-31 Novo Nordisk As compostos seletivos de pyy e usos dos mesmos
CR20180058A (es) 2015-09-04 2018-02-26 Hoffmann La Roche Nuevos derivados de fenoximetilo
CA2991615A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6846414B2 (ja) 2015-09-24 2021-03-24 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
CN107614505B (zh) 2015-09-24 2021-05-07 豪夫迈·罗氏有限公司 作为双重atx/ca抑制剂的新型二环化合物
EP3353178B1 (en) 2015-09-24 2021-07-14 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
EP3717508A1 (en) 2017-12-01 2020-10-07 The University of Copenhagen Peptide hormone with one or more o-glycans
BR112020014624A2 (pt) 2018-02-02 2020-12-08 Novo Nordisk A/S Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
EP3800195A1 (en) * 2019-10-03 2021-04-07 Universitat de Barcelona Peptide compounds for reducing side effects of cb1 receptor agonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
WO1994022467A1 (en) 1993-03-29 1994-10-13 University Of Cincinnati Analogs of peptide yy and uses thereof
US6017879A (en) * 1998-04-03 2000-01-25 B.M.R.A. Corporation B.V. Template associated NPY Y2-receptor agonists
US7811989B2 (en) * 2003-01-17 2010-10-12 Ipsen Pharma S.A.S. Peptide YY analogs
WO2005053726A1 (en) * 2003-11-25 2005-06-16 Bayer Pharmaceuticals Corporation Selective neuropeptide y2 receptor agonists
EP1789440A4 (en) * 2004-02-11 2008-03-12 Amylin Pharmaceuticals Inc REASONS FOR THE FAMILY OF PANCREATIC POLYPEPTIDES AND POLYPEPTIDES CONTAINING THEM

Also Published As

Publication number Publication date
EP1844070B1 (en) 2011-03-02
ATE500268T1 (de) 2011-03-15
DK1844070T3 (da) 2011-06-14
PL1844070T3 (pl) 2011-07-29
US7410949B2 (en) 2008-08-12
NO20073664L (no) 2007-09-28
RU2383553C2 (ru) 2010-03-10
DE602006020407D1 (de) 2011-04-14
BRPI0606675A2 (pt) 2009-07-07
RU2007131504A (ru) 2009-02-27
KR100905380B1 (ko) 2009-06-30
AU2006207659B2 (en) 2009-10-29
MX2007008614A (es) 2007-09-11
EP1844070A1 (en) 2007-10-17
PT1844070E (pt) 2011-05-04
ZA200705674B (en) 2009-08-26
WO2006077035A1 (en) 2006-07-27
KR20070095422A (ko) 2007-09-28
JP2008527017A (ja) 2008-07-24
WO2006077035A9 (en) 2006-10-26
TW200637874A (en) 2006-11-01
IL184428A0 (en) 2007-10-31
JP4633804B2 (ja) 2011-02-16
ES2359850T3 (es) 2011-05-27
CN101107266A (zh) 2008-01-16
TWI309653B (en) 2009-05-11
US20060160742A1 (en) 2006-07-20
CA2594423A1 (en) 2006-07-27
AU2006207659A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
ECSP088120A (es) Derivados de piridazinona como agonistas del receptorde la hormona tiroidea
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CR9748A (es) Derivados de xantina como agonistas selectivos de hm74a
CR10489A (es) Derivados fenil-pirazol como ligandos de receptores glucocorticoides no esteroides
CR7743A (es) Nuevos compuestos de oxazol y tiazol como inhibidorea del factor de crecimiento transformador (tgf)
GT200600114A (es) Derivados de ciclopropanocarboxamida
CL2011000544A1 (es) Compuestos derivados de benzamida n sustituida por heterociclo, ligandos de los receptores cannabinoides; composicion farmaceutica; y su uso para tratar el dolor, entre otras enfermedades.
CR8270A (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
ECSP109934A (es) Compuesto - 946
ECSP12011606A (es) Agonistas de gpr119
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
PA8805801A1 (es) Agonistas novedosos de los receptores de glucorticoides
UY31570A1 (es) Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
UY30640A1 (es) Compuestos
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
CR11264A (es) Compuestos de 5-(4-halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
NO20085099L (no) Puritonderivativer som HM74A agonister
IN2012DN03042A (es)
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas

Legal Events

Date Code Title Description
FG Grant, registration